Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo

Chimeric antigen receptor T (CAR-T) cell targeting CD19 antigen has achieved exhilarative clinical efficacy in B-cell malignancies. However, challenges still remain for the currently approved anti-CD19 CAR-T therapies, including high recurrence rates, side effects and resistance. Herein, we aim to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Zhiqiang, Shi, Jiaru, Jiang, Qiyao, Yu, Guohua, Li, Xiaorui, Yu, Zhuoying, Wang, Jianxun, Shi, Yuanyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985527/
https://www.ncbi.nlm.nih.gov/pubmed/36871129
http://dx.doi.org/10.1186/s43556-023-00122-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985527/
https://www.ncbi.nlm.nih.gov/pubmed/36871129
http://dx.doi.org/10.1186/s43556-023-00122-6

Ejemplares similares